- Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease - - Prasinezumab is a potential ...

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...

Researchers have discovered how a surface protein on brain cells, called Aplp1, can play a role in spreading material ...

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is conducting a ...

Australian-founded medical technology company SYMBYX today announced compelling results from a 72-week randomized controlled ...

Introduction Although there are some drugs to control Parkinson’s disease (PD), they have several side effects and cannot ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

Mission Therapeutics, a clinical-stage biotechnology company, has raised $13.3m to advance the clinical development of its lead Parkinson’s disease (PD) candidate, MTX325, into a phase 1b ...

Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class ...